×
About 9,845 results

ALLMedicine™ Plaque Psoriasis Center

Research & Reviews  2,342 results

Commentary: Early Diagnosis of PsA, February 2023
https://www.mdedge.com/rheumatology/article/260916/psoriatic-arthritis/commentary-early-diagnosis-psa-february-2023
Vinod Chandran, MBBS, MD, DM, PhD

Jan 30th, 2023 - Vinod Chandran, MBBS, MD, DM, PhD Most patients develop psoriatic arthritis (PsA) after the onset of cutaneous psoriasis. The path toward long-term remission of PsA may be by early diagnosis and effective treatment prior to the onset of joint dama.

Fluorescence-optical imaging may detect preclinical PsA
https://www.mdedge.com/rheumatology/article/260899/psoriatic-arthritis/fluorescence-optical-imaging-may-detect-preclinical
Heidi Splete

Jan 27th, 2023 - Fluorescence-optical imaging (FOI) identified early signs of psoriatic arthritis, based on data from 2 years of follow-up of a cohort of 389 adults at 14 rheumatology centers. Approximately 25% of individuals with psoriasis go on to develop psoria.

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
https://clinicaltrials.gov/ct2/show/NCT05701995

Jan 27th, 2023 - The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

Long-term clinical trials of biologics in plaque psoriasis demonstrate heterogeneous st...
https://doi.org/10.1093/bjd/ljac142
The British Journal of Dermatology; Grolleau C, Le Cleach L et. al.

Jan 27th, 2023 - Long-term clinical trials of biologics in plaque psoriasis demonstrate heterogeneous study designs.|2023|Grolleau C,Le Cleach L,Shourick J,Sbidian E,Afach S,|

Fluorescence-optical imaging detects early transition from psoriasis to PsA
https://www.mdedge.com/rheumatology/article/260848/psoriatic-arthritis/fluorescence-optical-imaging-detects-early

Jan 26th, 2023 - Key clinical point: Fluorescence-optical imaging (FOI) successfully detected the early signs of musculoskeletal inflammation in hands and predicted transition from psoriasis to psoriatic arthritis (PsA) at initial stages in patients with psoriasis.

see more →

Guidelines  2 results

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older/
Arcutis Biotherapeutics, Inc.

Jul 29th, 2022 - WESTLAKE VILLAGE, Calif., July 29, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced today that t...

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.

Jan 7th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

see more →

Drugs  147 results see all →

Clinicaltrials.gov  672 results

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
https://clinicaltrials.gov/ct2/show/NCT05701995

Jan 27th, 2023 - The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03536884

Jan 26th, 2023 - The study consists of a 48-week double-blind Treatment Period, an optional 96-week open-label extension (OLE) Period and an optional 48-week OLE2 Period for eligible subjects in the USA and Canada.

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT03598790

Jan 26th, 2023 - The study consists of a 144-week Treatment Period (open-label) and an optional 48-week Open-Label Extension Period 2 (OLE2) for eligible subjects in the USA and Canada.

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizu...
https://clinicaltrials.gov/ct2/show/NCT04862286

Jan 26th, 2023 - Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study evaluates adverse events and change in disease activity with risankizumab in pediatric parti...

2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis,...
https://clinicaltrials.gov/ct2/show/NCT05155098

Jan 26th, 2023 - After the baseline visit, data will be collected for each patient prospectively every 6 months for up to 2 years. At each visit, effectiveness parameters, as well as the patients' QoL and treatment pattern will be documented.

see more →

News  762 results

Commentary: Early Diagnosis of PsA, February 2023
https://www.mdedge.com/rheumatology/article/260916/psoriatic-arthritis/commentary-early-diagnosis-psa-february-2023
Vinod Chandran, MBBS, MD, DM, PhD

Jan 30th, 2023 - Vinod Chandran, MBBS, MD, DM, PhD Most patients develop psoriatic arthritis (PsA) after the onset of cutaneous psoriasis. The path toward long-term remission of PsA may be by early diagnosis and effective treatment prior to the onset of joint dama.

Fluorescence-optical imaging may detect preclinical PsA
https://www.mdedge.com/rheumatology/article/260899/psoriatic-arthritis/fluorescence-optical-imaging-may-detect-preclinical
Heidi Splete

Jan 27th, 2023 - Fluorescence-optical imaging (FOI) identified early signs of psoriatic arthritis, based on data from 2 years of follow-up of a cohort of 389 adults at 14 rheumatology centers. Approximately 25% of individuals with psoriasis go on to develop psoria.

Fluorescence-optical imaging detects early transition from psoriasis to PsA
https://www.mdedge.com/rheumatology/article/260848/psoriatic-arthritis/fluorescence-optical-imaging-detects-early

Jan 26th, 2023 - Key clinical point: Fluorescence-optical imaging (FOI) successfully detected the early signs of musculoskeletal inflammation in hands and predicted transition from psoriasis to psoriatic arthritis (PsA) at initial stages in patients with psoriasis.

Abbvie expects sales of two drugs to exceed $21 bln in 2027
https://www.reuters.com/article/abbvie-outlook/abbvie-expects-sales-of-two-drugs-to-exceed-21-bln-in-2027-idUSL4N33V2OW

Jan 10th, 2023 - Jan 10 (Reuters) - AbbVie said on Tuesday it expects combined peak sales of plaque psoriasis drug Skyrizi and anti-inflammatory medicine Rinvoq to exceed $21 billion in 2027. (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)

Topical psoriasis treatments
https://www.mdedge.com/dermatology/article/260398/psoriasis
Heidi Splete

Dec 29th, 2022 - LAS VEGAS – Although the range of oral psoriasis therapies continues to expand, “topical therapy is still the cornerstone of the treatment of psoriasis,” said Linda Stein Gold, MD, in a presentation at Medscape Live’s annual Las Vegas Dermatology.

see more →

Patient Education  13 results see all →